DAB2IP and breast cancer: For instance, Olsen et al. showed that loss of expression of the RasGAP tumor suppressor DAB2IP — often along with loss of another RasGAP, RASAL2 — promotes poorer outcome in approximately 50% of Luminal B breast cancer, which is associated with Ras signaling pathways and NF-κB transcription factor activity (7).